Eagle Pharmaceuticals, Inc (EGRX) Fair Value & Analysis
Healthcare · US · Market cap $3.3M
Eagle Pharmaceuticals, Inc
EGRX · US
Fair value as of: Jul 17, 2026
From 26 valuation models · updated today
Fair value updated Jul 17, 2026, revised from $71.24 to $0.2146 (−99.7%) since Jun 24, 2026. Share price −3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0010 – $3.74 · fair‑value band $0.1610 – $0.3514 · the $0.5950 price screens above the $0.2146 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Eagle Pharmaceuticals, Inc (EGRX) currently trades at $0.5950, while our model-based Fair Value estimate is $0.2146, implying the stock looks roughly 63.9% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Eagle Pharmaceuticals, Inc generated revenue of $258M at a net margin of 4.6%. Revenue declined 12.8% year over year. It earns a return on equity of 4.9%. Net debt stands at $12.5M. Fundamentals as of Jul 17, 2026
Our scenario range runs from $0.1610 (bear case) to $0.3514 (bull case); at $0.5950, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside, at -64%, EGRX screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the …
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Eagle Pharmaceuticals, Inc reported revenue of $317M in FY2022 versus $213M in FY2018, a compound +10.4%/yr. Reported net income was $35.6M in FY2022, compounding +2.8%/yr from FY2018.
Is EGRX fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Eagle Pharmaceuticals, Inc (EGRX) undervalued?
What is the fair value of EGRX?
What is the quality score of EGRX?
What is the revenue of Eagle Pharmaceuticals, Inc (EGRX)?
What is the net profit margin of EGRX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Eagle Pharmaceuticals, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Eagle Pharmaceuticals, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.